Aberrant neuroendocrine signaling is frequent yet poorly understood feature of prostate cancers. Membrane metalloendopeptidase (MME) is responsible for the catalytic inactivation of neuropeptide substrates, and is downregulated in nearly 50% of prostate cancers. However its role in prostate carcinogenesis, including formation of castration-resistant prostate carcinomas, remains uncertain. Here we report that MME cooperates with PTEN in suppression of carcinogenesis by controlling activities of prostate stem/progenitor cells. Lack of MME and PTEN results in development of adenocarcinomas characterized by propensity for vascular invasion and formation of proliferative neuroendocrine clusters after castration. Effects of MME on prostate stem/progenitor cells depend on its catalytic activity and can be recapitulated by addition of the MME substrate, gastrin-releasing peptide (GRP). Knockdown or inhibition of GRP receptor (GRPR) abrogate effects of MME deficiency, and delay growth of human prostate cancer xenografts by reducing the number of cancer propagating cells. In sum, our study provides a definitive proof of tumor suppressive role of MME, links GRP/GRPR signaling to the control of prostate stem/progenitor cells, and shows how dysregulation of such signaling may promote formation of castrationresistant prostate carcinomas. It also identifies GRPR as a valuable target for therapies aimed at eradication of cancer propagating cells in prostate cancers with MME downregulation.
Introduction
Prostate cancer is the most frequently diagnosed cancer and is the second leading cause of cancer-related death in men in the United States 38 . While most prostate cancers are adenocarcinomas, a significant percentage also have dysregulation of neuroendocrine signaling, such as excessive accumulation of cells with neuroendocrine differentiation and/or overproduction of neuropeptides 8, 19, 27 . A large amount of data demonstrate neuropeptides, such as gastrin-releasing peptide (GRP), are associated with accelerated prostate cancer progression and inferior prognosis 34, 45, 48 . GRP can promote cell proliferation, and accelerate migration and invasion of prostate cancer cells 15, 34, 41, 54 . Targeting of the GRP receptor suppresses growth in cell culture and xenograft models 26 . However, specific mechanisms by which neuropeptide dysregulation contributes to the pathogenesis of prostate cancer remain insufficiently elucidated.
Local concentration of neuropeptides is regulated in part by membrane metalloendopeptidase (MME, aka Neutral endopeptidase). MME is a cell-surface peptidase member of the M13 family of zinc peptidases, which also includes endothelin converting enzymes (ECE-1 and ECE-2), KELL and PEX. MME cleaves peptide bonds on the amino side of hydrophobic amino acids and is the key enzyme in processing of a variety of physiologically active peptides, such as GRP, neurotensin, and vasoactive intestinal peptide 10, 54 . MME is downregulated in nearly 50% of primary and metastatic prostate cancers, independently predicting an inferior prognosis 12, 17, 30 . In addition to its downregulation by androgen withdrawal 37, 55 , MME expression is also downregulated by methylation, suggesting its tumor suppressive effects 30, 49 . Indeed, MME expression reduces growth, motility 41 , and survival 40, 42 of prostate cancer cells in cell culture. Consistent with these observations, replacements of MME inhibit tumorigenicity of prostate cancer cells in xenograft experiments 7, 14 . Nevertheless, mice lacking Mme show no prostate cancer-related phenotype 24 , and the role of MME in prostate cancer progression remains uncertain.
At least part of MME effects are mediated by the PI3K/AKT pathway that plays a key role in multiple cellular processes including cell survival, proliferation, and cell migration reviewed in 44 . MME associates with and stabilizes the PTEN tumor suppressor protein, resulting in increased PTEN phosphatase activity, thereby inhibiting AKT activating phosphorylation 43 . MME may also have PTEN independent mechanisms of AKT inhibition by processing neuropeptides, such as GRP, which are known to activate AKT 42 . Consistent with a possibility of potential cooperation between MME and PTEN in suppression of carcinogenesis, downregulation of MME is observed in 42% and 63% of PTEN deficient cases of human primary and metastatic prostate cancers, respectively 46 . However, it remains unknown if catalytically dependent neuropeptide-based mechanisms of MME tumor suppression play a role in prostate cancer progression.
The mouse prostate is composed of a series of branching ducts, each containing distal and proximal regions relative to the urethra 39 . Proliferating, transit-amplifying cells are preferentially located in the distal region of the prostatic ducts, whereas cells with stem cell-like properties, such as low cycling rate, self-renewal ability, high ex vivo proliferative potential, and androgen withdrawal resistance, mainly reside in the proximal region of the prostatic ducts 5, 36, 47, 57,Fu, 2018 #17167 . Thus, approaches based on the isolation of cells according to their displayed stem cell-specific markers can be complemented by careful evaluation of stem cell compartments in situ.
In the current study, we used autochthonous mouse model of prostate neoplasia associated with deficiency of Pten tumor suppressor gene. In this model, prostate carcinogenesis is initiated by the prostate epithelium-specific inactivation of Pten driven by PB-Cre4 transgene (PtenPE-/-mice; 3, 16, 23, 50, 53, 56 . The majority of mice show early stages of prostate cancer, such as high-grade prostatic intraepithelial neoplasms (HG-PINs) and few animals show early adenocarcinomas characterized by stromal invasion. Thus, it is well suitable for testing if additional genetic alterations, such as Mme inactivation, may accelerate cancer progression. We report that lack of both MME and PTEN leads to aggressive prostate cancers manifesting frequent vascular invasion and increased neuroendocrine differentiation after castration. Formation of such cancers is preceded by morphologically detectable neoplastic lesions at the prostate stem/progenitor cell compartment. The effect of MME deficiency on stem/progenitor cells can be recapitulated by its substrate GRP and is abrogated by either GRP receptor (GRPR) antagonist or GRPR siRNA knockdown. Knockdown or inhibition of GRP receptor (GRPR) delay growth of human prostate cancer xenografts by reducing the pool of cancer propagating cells.
Results

MME cooperates with PTEN in suppression of prostate cancer in autochthonous mouse model
To test the cooperation of Mme and Pten genes in suppression of prostate cancer in vivo we first evaluated MME expression in HG-PINs and early invasive adenocarcinomas typical for Pten PE-/mice. While irregular MME expression was observed in the majority of neoplastic lesions, MME was absent in the areas of stromal invasion ( Fig. 1 and Supplementary Fig. 1 ). No significant alterations in MME expression were detected in the proximal regions of prostatic ducts, consistent with the lack of neoplastic lesions in that part of the prostate in Pten PE-/mice ( Fig. 2a , Supplementary Fig. 2a , and Supplementary Table 1 ). Consistent with the reported regulation of MME by the androgen receptor (AR) 29, 37, 55 , castration of both WT and Pten PE-/mice resulted in downregulation but not complete abrogation of MME expression ( Fig. 2 ).
Next, we tested if MME deficiency can accelerate prostate carcinogenesis in Pten PE-/mouse model. We crossed Mme -/and Pten PE-/mice, and evaluated prostates of age-matched wild-type (WT), Mme -/-, Pten PE-/and Mme -/-Pten PE-/strains ( Fig. 2 , Supplementary Fig. 2 , and Supplementary Table 1 ). Consistent with previous observations 24 , Mme -/mice did not develop any neoplastic lesions by 16 months of age, while Pten PE-/mice showed low-and high-grade PINs at 3 months. At 16 months 29% of Pten PE-/mice developed early invasive adenocarcinomas, characterized by separate nests of neoplastic cells in desmoplastic stroma ( Fig. 2 and Supplementary   Table 1 ). All neoplastic lesions were in the distal regions of prostatic ducts. Eighty six percent of Mme -/-Pten PE-/mice developed adenocarcinomas in the same location (Fisher's exact test P=0.0025). Furthermore, contrary to Pten PE-/mice, Mme -/-Pten PE-/mice developed dysplastic lesions followed by adenocarcinomas in the proximal regions of the prostatic ducts ( Fig. 2a , Supplementary Fig. 1 and Supplementary Table  1 ). Some adenocarcinomas of Mme -/-Pten PE-/mice showed distinct vascular invasion, a feature not characteristic for prostatic lesions in Pten PE-/mice ( Fig. 2a and Supplementary Fig. 2 and 3 ). Consistent with these histological observations, prostatic epithelium of Mme -/-Pten PE-/mice was characterized by significantly higher proliferative rate according to Ki67 staining ( Fig. 2 and Supplementary Fig. 2 ), expressed higher amounts of epigenetic reprogramming factor EZH2 ( Fig. 2 and Supplementary Fig. 4 ), and showed increased number of CK5 and p63 positive cells ( Supplementary Fig. 2 ) as compared to prostatic lesions in Pten PE-/mice. Prostatic epithelium lesions of Mme -/-Pten PE-/mice also showed higher levels of pAKT ( Fig. 2 and Supplementary Fig. 4 ), confirming additional MME-dependent mechanisms of regulation of this downstream target of PTEN 42, 43 . Consistent with our previous observation 23 , prostatic neoplastic lesions of Pten PE-/mice had increased number of synaptophysin positive neuroendocrine cells in the distal regions of prostatic ducts ( Fig.   2 and Supplementary Fig. 2 ). However, this number was not additionally elevated in Mme -/-Pten PE-/mice. In sum, lack of both MME and PTEN not only promoted lesions typically observed in the prostates of Pten PE-/mice, but also resulted in a distinct new neoplasms located in the proximal regions of prostatic ducts.
MME loss leads to more aggressive tumor phenotype with increased proliferation of neuroendocrine clusters after castration
As compared to Pten PE-/mice, recurrent tumors in all castrated Mme -/-Pten PE-/mice (n=8) had increased levels of phosphorylated MET, and reduced expression of Ecadherin, signatures of more aggressive phenotype (Fig. 3 ). As previously reported 23 , recurrent tumors in castrated Pten PE-/mice show decreased expression of AR and increased number of neuroendocrine cells. MME deficiency in castrated Pten PE-/mice did not further affect AR expression levels ( Fig. 3 ). However, recurrent tumors in Mme -/-Pten PE-/mice had higher frequency of neuroendocrine clusters (≥ 3 cells) and such clusters were more proliferative according to Ki67 staining ( Fig. 3 ). Thus, MME deficiency promotes the increase in neuroendocrine differentiation of neoplastic cells after castration.
MME loss promotes activities of PTEN-deficient mouse prostate stem/progenitor cells
The proximal regions of prostatic ducts are particularly enriched in prostate epithelium stem/progenitor cells 5, 13, 36, 47, 57 . Thus we evaluated potential effects of MME and PTEN deficiency on prostate stem/progenitor cells, isolated as the CD49f hi /Sca-1 + fraction by fluorescence-activated cell sorting (FACS). Mme -/mice had the same number of stem/progenitor cells as age-matched WT mice (5.7% vs 5.6%). In contrast, Pten PE-/mice showed a significant increase of the stem cell pool (8.4%) consistent with previous reports suggesting PTEN's involvement in regulation of prostate stem/progenitor cells 9, 28, 51 . The pool of CD49f hi /Sca-1 + cells deficient for both PTEN and MME, constituted 12.1% of the prostate epithelium, representing an additional 44% increase as compared to PTEN deficient CD49f hi /Sca-1 + cells (Fig. 4a, P<0 .0001).
Formation of prostaspheres is used as a functional cell culture test for presence, growth and self-renewal potential of prostate stem/progenitor cells. Consistent with FACS results, CD49f hi /Sca-1 + cells isolated from prostates of Mme -/-Pten PE-/mice showed the highest frequency of prostaspheres in multiple consecutive sphere dissociation and regeneration passages ( Fig. 4b ). Furthermore, prostaspheres deficient for both genes had larger size, as compared to WT, MME or PTEN deficient stem/progenitor cells ( Fig. 4c ). In all groups CD49f lo /Sca-1luminal cells formed very few spheres after the first plating and no spheres were observed after the first passage ( Fig. 4d ). Thus, it is unlikely that the increase in prostaspheres in PTEN and MME deficient cells resulted from a reprograming of differentiated cells towards a stem cell state.
To directly test if the observed results represent direct effects of MME and/or PTEN on prostate stem/progenitor cells we isolated CD49f hi /Sca-1 + stem/progenitor cells and CD49f lo /Sca-1luminal cells from prostates of WT, Mme -/-, Pten loxP/loxP , and Mme -/-Pten loxP/loxP mice and infected them with adenovirus expressing Cre recombinase (Ad-Cre). Consistent with our previous experiments, lack of both Pten and Mme had the most pronounced effect on frequency of CD49f hi /Sca-1 + stem/progenitor cells in consecutive passages ( Fig. 4e ). Luminal cells formed only few spheres with the same frequency in all groups (Fig. 4f ). Taken together, these results showed that MME cooperates with PTEN in regulation of prostate stem/progenitor cell functions.
GRP promotes activities of PTEN-deficient mouse prostate stem/progenitor cells
To identify mechanisms by which MME may affect regulation of prostate stem/progenitor cells, we next examined the expression of MMEs main substrates, GRP, neurotensin (NT) and vasoactive intestinal peptide (VIP) in the prostates of WT, Mme -/-, and Pten PE-/and Mme -/-Pten PE-/strains. Strong GRP expression was detected only in prostates of Mme -/-Pten PE-/mice, while NT and VIP were not detected in all cases ( Supplementary Fig. 5 ).
To test if GRP could recapitulate the effects of MME deficiency, we isolated prostate cells from Mme -/-Pten PE-/mice, and either performed knockdown of GRP receptor (GRPR, Fig. 5a ) or administered GRPR antagonist ([Tyr 4 , D-Phe 12 ]-Bombesin. Both approaches reversed effects of MME deficiency on size and formation frequency of prostaspheres ( Fig. 5b and 5c ).
Consistent with the observation of frequent vascular invasion by prostate adenocarcinomas in Mme -/-Pten PE-/mice, we detected increased cell motility and invasion of prostate cells isolated from Mme -/-Pten PE-/mice, as compared to those prepared from Pten PE-/mice ( Fig. 5d and 5e ). This effect was reversed by either GRPR knockdown or treatment with [Tyr 4 , D-Phe 12 ]-Bombesin. We next isolated prostate cells form Pten PE-/mice, and treated them with the MME enzyme inhibitor Thiorphan. Sphere size ( Fig. 5f ), sphere forming capacity ( Fig. 5g ), cell motility (Fig. 5h ), and invasion ( Fig. 5l ) were each increased by MME catalytic inhibition; and more importantly Grpr siRNA knockdown or a GRPR antagonist abrogated the stimulated functions of MME enzyme inhibition on the prostate cells form Pten PE-/mice. Finally, to test if GRP directly affects the function of PTEN-deficient prostate stem/progenitor cells, CD49f hi /Sca-1 + prostate stem cells isolated from Pten loxP/loxP were infected with Ad-Cre followed by treatment with GRP and/or [Tyr 4 , D-Phe 12 ]-Bombesin. GRP addition reproduced the effects of MME deficiency on formation frequency and size of prostasphere, while these effects were abrogated by [Tyr 4 , D-
Phe 12 ]-Bombesin ( Fig. 5j and 5k ). Taken together, these data suggest that the MME substrate GRP mediates in part the growth and invasive effect of PTEN-deficient prostate cells observed in association with loss or catalytic inhibition of MME; and GRP is a key MME target responsible for stimulating prostate stem/progenitor cells.
GRP promotes expansion of human prostate cancer propagating cells
To further assess the relevance of our observations to human disease we tested the effects of GRP and [Tyr 4 , D-Phe 12 ]-Bombesin on PTEN-deficient androgen-refractory human prostate cancer cells DU145 and PC3. Consistent with previous reports 34, 41, 48 , GRP promoted cell proliferation, migration, and invasion, and these effects were negated by addition of [Tyr 4 , D-Phe 12 ]-Bombesin in both cell lines ( Supplementary Fig.  6 ). Similar effects cell migration and invasion were also observed in androgensensitive human prostate adenocarcinoma cells LNCaP ( Supplementary Fig. 7 ). In agreement with our observations on mouse prostate epithelium cells, GRPR knockdown rescued the stimulating effects of GRP and inhibitory effects of [Tyr4, D-Phe12]-Bombesin, suggesting the crucial role of GRP/GRPR in control of the above parameters in both species ( Supplementary Fig. 6 and 7 ). GRP treatment also increased expression of synaptophysin in DU145, PC3 cells and LNCaP cells, thereby suggesting that GRP/GRPR signaling may influence neuroendocrine commitment ( Supplementary Fig. 8 ).
Next we tested if GRP/GRPR signaling has an immediate effect on prostate cancer cells with stem cell-like properties. Such cells, called cancer propagating or cancer stem cells 13, 18 , are characterized by their ability for long-term self-renewal, high potential for proliferation, high tumorigenicity, capacity to generate the whole spectrum of heterogeneity of their original tumors, and resistance to androgen withdrawal. Prostate cancer propagating cells can be isolated by either high enzymatic activity of ALDH (ALDEFLUOR assay) 22 or by detection of CD44 expression 33 . In both approaches cancer propagating cells isolated from DU145, PC3 and LNCaP cells were increased in number after GRP treatment ( Fig. 6a-6d and Supplementary Fig.  7e and f). Cancer propagating cells also formed spheres in greater number and size. These changes were diminished by [Tyr 4 , D-Phe 12 ]-Bombesin and/or GRPR siRNA ( Fig. 6a-6g ).
To study the effect of GRP on human prostate cancer xenografts in vivo, immunodeficient NSG mice were subcutaneously injected with PC-3 cells and treated with [Tyr 4 , D-Phe 12 ]-Bombesin when the tumor size reached 10 mm 3 (Fig. 6h-6j ). Daily intraperitoneal injections of [Tyr 4 , D-Phe 12 ]-Bombesin reduced both tumor volume and weight by 70% by the time of animal euthanasia at 26 days after the beginning of treatment. Importantly, according to the ALDEFLUOR assay, a fraction of prostate cancer propagating cells was significantly reduced in tumors treated with [Tyr 4 , D-Phe 12 ]-Bombesin as compared to controls treated with vehicle alone. The same outcomes have been observed after transplantation of PC3 cells infected with lentivirus expressing GRPR shRNA ( Supplementary Fig. 9 ). Thus, the effects of GRP/GRPR signaling abrogation in inhibiting prostate cancer cell tumorigenicity result from diminishing the population of cancer propagating cells.
Discussion
Our study provides direct genetic support to previous reports proposing Mme role as a tumor suppressor gene. Our findings show that Mme cooperates with Pten in suppression of prostate carcinogenesis. Lack of Mme leads to formation of advanced adenocarcinomas characterized by intravascular invasion, a feature not observed adenocarcinomas of Pten PE-/mice. In agreement with their more aggressive behavior adenocarcinomas of composite mice also have higher proliferative rate, increased number of CK5 and p63 positive cells and elevated levels of EZH2 expression.
It has been reported previously, that Pten conditional deletion in the prostate epithelium leads to basal cell proliferation with concomitant expansion of the prostate stem/progenitor-cell like Sca-1 + and BCL-2 + subpopulation 51 . CD49f hi /Sca-1 + Ptendeficient neoplastic cells exhibits cancer propagating cell properties, such as high sphere-forming capacity, sustained self-renewal, increased proliferation, and tumorigenic potential, as compared with other isogenic subpopulations 9, 28 . According to our studies, the combined Mme and Pten deficiency leads to further increase of number and growth potential of prostate stem/progenitor cells. These observations suggest that Mme and Pten cooperate in controlling stem/progenitor cells. However, since lack of Pten may also stimulate a basal to luminal transdifferentiation in conjunction with proliferation 6, 20, 52 , further studies are needed to evaluate the role of cell plasticity as an additional factor influencing effects of combined Mme and Pten deficiency. Our findings also show that the lack of both Mme and Pten leads to the formation of dysplastic lesions and adenocarcinomas in the proximal regions of prostatic ducts, the structures particularly enriched in stem/progenitor cells. Thus Mme may playing a particularly critical role at the site of prostate stem/progenitor cell niche.
Our findings also show that effects of MME on prostate stem/progenitor cells depend on the presence of its downstream effector, GRP, Furthermore, we have observed that abrogation of GRP/GRPR signaling may diminish the pool of cancer propagating cells, thereby highlighting an important role of neuroendocrine signaling in the regulation of cell stemness. Previously, prostate cancer propagating cells have been shown to be regulated by the PTEN/PI3K/AKT pathway 9 . Our study suggests that this effect is induced by neuropeptide signaling regulated by MME and is potentiated by MME loss. This provides a rationale for using the MME/GRP pathway for targeting of cancer propagating cells, perhaps as a part of combinatorial therapy approaches.
Our study shows that accelerated progression of prostate carcinomas associated with MME deficiency is not associated with increase in the number of neuroendocrine cells. Neuroendocrine cells are important for prostate development 4 . The majority of human prostate adenocarcinomas and mouse models associated with Pten deficiency contain neuroendocrine cells 23, 58 . However, with the exception of highly aggressive neuroendocrine/small cell carcinomas, it remains debatable if increased number of neuroendocrine cells, as defined by their expression of neuroendocrine markers, such as synaptophysin and calcitonin gene-related peptide, are essential for the accelerated progression of pre-castrate prostate adenocarcinoma 1, 2, 45 . Our study suggests that accumulation of un-cleaved neuropeptides may mitigate the requirement for neuroendocrine cell expansion or lead to a feedback inhibition of neuroendocrine cell differentiation in MME-deficient prostate cancers. The recent introduction of therapies that better target the androgen axis has led to a significant increase in frequency of castrate-resistant prostate cancer with neuroendocrine differentiation 8 . It has been shown that inactivation of the RB1 tumor suppressor gene increases cell plasticity along with the promotion of an aggressive neuroendocrine phenotype 19, 27, 32 . In castrated mice with combined Pten and Trp53 deficiency some prostate tumors arising from luminal cells had regions of highly proliferative cells with overt neuroendocrine differentiation. However, other tumors showed only limited foci of neuroendocrine differentiation without any detectable proliferation 58 . In this report Pten inactivation alone resulted in modest increase in neuroendocrine foci, consistent with our findings. In our model associated with Pten and Mme deficiency we observed increased number of neuroendocrine neoplastic clusters and increased proliferation in such clusters after castration. Furthermore, as compared to Pten PE-/mice, recurrent tumors in castrated Mme -/-Pten PE-/mice had more aggressive phenotype based on increased levels of phosphorylated MET, and reduced expression of E-cadherin. The mechanisms by which MME deficiency facilitates neuroendocrine trans-differentiation of the prostate epithelium or leads to expansion neuroendocrine cell lineage after castration remain to be investigated. It also remains to be investigated if MME deficiency represents an alternative to RB1 loss for progression of some castrate-resistant prostate cancer. Our mouse model based on inactivation of Mme and Pten should offer an important tool for answering these important questions of prostate cancer pathogenesis and testing new therapeutic approaches.
Materials and Methods
Mice. ARR2PB-Cre transgenic male mice on FVB/N background (PB-Cre4) 53 were crossed with Pten loxP/loxP 21 female mice on the 129/BALB/c background. Resulting PB-Cre4Pten loxP/loxP male mice were designated as Pten PE-/mice. Pten PE-/male mice were crossed with Mme null female mice on C57BL6 background (Mme -/-) 24 . Offspring with PB-Cre4 Mme -/-Pten loxP/loxP genotype were designated as Mme -/-Pten PE-/mice. To minimize the confounding effects of genetic background Pten PE-/and Mme -/-Pten PE-/mice were backcrossed to FVB/N for at least 10 crosses and all control experiments were performed on age and sex-matched randomized mice of the same background. Castration experiments. Male mice were weighed and anesthetized using isoflurane. Pressure was applied to the abdomen of each mouse to push both testes down into the scrotal sac. An approximately 1 cm incision was made across the midline of the scrotal sac to expose the testicular membrane. The midline between the left and right testes sacs were located and a small incision is made on the left side of the membrane midline. The testes, attached fatty tissue, the vas deferens and associated blood vessels are carefully pulled out through the incision. The blood vessels were cauterized and the testes was removed by severing below the cauterization. Same procedure was repeated to remove testes from the right side of the midline. Remaining tissue was pushed back into incision which was then closed with wound clips. Post procedure, the mouse was placed on a heating pad till it recovered from the effects of the anesthetic followed by placement in a clean cage with fresh chow and water.
Pathologic assessment. Moribund mice, as well as those sacrificed according to schedule, were anesthetized with avertin and, if necessary, subjected to cardiac perfusion at 90 mm Hg with PBS. After macroscopic evaluation during necropsy, lung, liver, prostate, and lymph nodes were fixed in phosphate-buffered 4% paraformaldehyde tissues, embedded in paraffin and 4-μm-thick sections were stained with Hematoxylin (Mayer's haemalum) and eosin. Striated muscle layer was used for identification of proximal (periurethral) and distal regions of prostatic ducts in transverse sections, as previously described 57 . Mouse prostatic intraepithelial neoplasia (PIN) and adenocarcinoma were defined according to earlier publications 5, 16, 31, 56 . Briefly, distal PIN 1 has 1 or 2 layers of atypical cells; PIN 2 has 3 or more layers of atypical cells, PIN 3 occupies the near entire glandular lumen; and PIN 4 fills and distorts the glandular profile, and is frequently marked by pronounced desmoplastic reaction. In agreement with the recent consensus report 16 , PIN1 and PIN2 represent low-grade PIN (LG-PIN) and PIN3 and 4 represent high-grade PIN (HG-PIN). Due to different architecture of the proximal regions of prostatic ducts, current PIN classification cannot be carefully applied to atypical proliferative lesions found in those structures. Thus we named those lesions as proximal duct dysplasia to stress their dissimilarity to PIN of distal regions of prostatic ducts. Given the complexity and controversial nature of the interpretation of stromal microinvasion we used term early adenocarcinoma only for neoplasms with invasive stromal growth confirmed by serial sections followed by 3D reconstruction. We used term advanced adenocarcinoma for neoplasms invading blood and lymphatic vessels. All pathological evaluations were performed in blinded fashion.
Cell culture. DU145, PC3 and LNCaP cell lines were obtained from the American Type Culture Collection (ATCC) and cultured in minimum essential medium (Cellgrow, #10-010-CV), F-12K (Cellgrow, #10-025-CV) and RPMI 1640 (VWR, cat # 4500-396), respectively, supplemented with 10% heat-inactivated fetal bovine serum (FBS, GIBCO, #16141-079) and Penicillin-Streptomycin (Cellgrow, #30-002-Cl). The cultures were maintained at 37ºC in a 5 % CO2 incubator. All cell lines were confirmed to be free of mycoplasma.
Primary mouse prostate cells were isolated following described procedures 5, 25 . were used for all knockdown experiments. MME inhibitor DL-Thiorphan, (1 μM, Sigma, #T6031) 35 was used to treat cells at 37°C for 20 min, followed by subsequent experiments. 5-bromo-2'deoxyuridine (BrdU) staining migration and invasion assays were performed as previously described 5, 11 .
ALDEFLUOR assay and Fluorescence Activated Cell Sorting. For detection of aldehyde dehydrogenase (ALDH) enzymatic activity, 10 6 cells were placed in ALDEFLUOR buffer and processed for staining with the ALDEFLUOR Kit (STEM CELL, #01700) according to the manufacture's protocol. Unstained and ALDH inhibitor (diethylaminobenzaldehyde, DEAB)-treated cells served as controls. For detection of CD44 expressing cancer cells, prostate cancer cells were stained for CD44 (BD Bioscience, #553134) to sort out CD44 positive and CD44 negative cells. Cell sorting and data analysis were performed on a FACS Aria II sorter equipped with the FACS DiVa software (BD Bioscience).
Prostasphere assay. The preparation of prostate epithelial cell suspensions, stem/basal cells, and luminal cells from male mice were performed based on previously described prostrate sphere assays 5, 25 Western blot. For western blot cell lysates were prepared using RIPA buffer (50 mM Tris-HCl, (pH 7.4), 1% Nonidet P-40, 0.25% Na-deoxicholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, Aprotinin, leupeptin, pepstatin: 1 μg/ml each, 1 mM Na3VO4, 1 mM NaF), followed by sonication for 10 seconds 5 times on ice. Lysates were then separated by 12% SDS-PAGE and transferred to PVDF membrane (Millipore #IPVH00010). The membrane was incubated overnight at 4ºC with antibodies to detect GRPR (Santa Cruz, #sc-32903, 1:1000), and GAPDH (Advanced Immunohistochemical Inc.; Long Beach, CA; #2-RGM2,1:5000), followed by incubation for 1 hour at room temperature with corresponding horseradish peroxidaseconjugated anti-rabbit secondary antibodies (Santa Cruz, #sc-2004, 1:2000) or antimouse secondary antibodies (Santa Cruz, #sc-2005, 1:2000) and developed using chemiluminescent substrate (Thermo Scientific, Rockford, IL, #34077).
Statistics.
Statistical analyses were performed with InStat 3.10 and Prism 7 software. (GraphPad, Inc., San Diego, CA). Two-tailed unpaired t-test, direct Fisher's tests, and log-rank Mantel-Haenszel test were used as appropriate. To ensure adequate power to detect a pre-specified effect size all sample sizes were chosen based on initial pilot experiments, including animal studies. No samples or animals were excluded from the analysis. The variance was similar between the groups that were statistically compared. Fig. 1 . Alterations of MME expression in prostate adenocarcinoma of Pten PE-/mice. MME expression in the proximal and distal regions of prostatic ducts of wildtype (WT) and Pten PE-/-12 months old mice, non-castrated and castrated at 5 months of age. Arrows indicate areas shown insets. Note that areas of stromal invasion (arrowheads) by early adenocarcinoma lacks MME expression in Pten PE-/mice. The ABC Elite method with hematoxylin counterstaining was performed. Scale bar, 60 μm and 30 µm (insets). Immunostainings are representative of six WT and six Pten PE-/mice, respectively. 
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